Research ArticleOriginal Article
Open Access

Calcification-associated molecular traits and therapeutic strategies in hormone receptor-positive HER2-negative breast cancer

Yuwei Li, Yuzheng Xu, Caijin Lin, Xi Jin, Ding Ma and Zhiming Shao
Cancer Biology & Medicine May 2024, 21 (5) 400-415; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0492

References

  1. 1.↵
    2. Siegel RL,
    3. Miller KD,
    4. Jemal A.
    Cancer statistics, 2020. CA Cancer J Clin. 2020; 70: 7–30.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Huppert LA,
    3. Gumusay O,
    4. Idossa D,
    5. Rugo HS.
    Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin. 2023; 73: 480–515.
    OpenUrl
  3. 3.↵
    2. Pusztai L,
    3. Yau C,
    4. Wolf DM,
    5. Han HS,
    6. Du L,
    7. Wallace AM, et al.
    Durvalumab with olaparib and paclitaxel for high-risk HER22-negative stage II/III breast cancer: results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021; 39: 989–98.e5.
    OpenUrlCrossRef
  4. 4.↵
    2. Sledge GW Jr.,
    3. Toi M,
    4. Neven P,
    5. Sohn J,
    6. Inoue K,
    7. Pivot X, et al.
    The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy - MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020; 6: 116–24.
    OpenUrl
  5. 5.
    2. Slamon DJ,
    3. Neven P,
    4. Chia S,
    5. Fasching PA,
    6. De Laurentiis M,
    7. Im SA, et al.
    Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018; 36: 2465–72.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Johnston SRD,
    3. Harbeck N,
    4. Hegg R,
    5. Toi M,
    6. Martin M,
    7. Shao ZM, et al.
    Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020; 38: 3987–98.
    OpenUrlCrossRefPubMed
  7. 7.
    2. Manohar PM,
    3. Davidson NE.
    Updates in endocrine therapy for metastatic breast cancer. Cancer Biol Med. 2021; 19: 202–12.
    OpenUrl
  8. 8.↵
    2. Li J,
    3. Jiang Z.
    Chinese society of clinical oncology breast cancer (CSCO BC) guidelines in 2022: stratification and classification. Cancer Biol Med. 2022; 19: 769–73.
    OpenUrlFREE Full Text
  9. 9.↵
    2. Smith RA,
    3. Andrews KS,
    4. Brooks D,
    5. Fedewa SA,
    6. Manassaram-Baptiste D,
    7. Saslow D, et al.
    Cancer screening in the united states, 2019: a review of current american cancer society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019; 69: 184–210.
    OpenUrlCrossRefPubMed
  10. 10.
    2. Conti A,
    3. Duggento A,
    4. Indovina I,
    5. Guerrisi M,
    6. Toschi N.
    Radiomics in breast cancer classification and prediction. Semin Cancer Biol. 2021; 72: 238–50.
    OpenUrl
  11. 11.
    2. Ding R,
    3. Xiao Y,
    4. Mo M,
    5. Zheng Y,
    6. Jiang YZ,
    7. Shao ZM.
    Breast cancer screening and early diagnosis in chinese women. Cancer Biol Med. 2022; 19: 450–67.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    2. Huang Y,
    3. Wang H,
    4. Lyu Z,
    5. Dai H,
    6. Liu P,
    7. Zhu Y, et al.
    Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer. Cancer Biol Med. 2021; 19: 1375–84.
    OpenUrl
  13. 13.↵
    2. Kim S,
    3. Tran TXM,
    4. Song H,
    5. Park B.
    Microcalcifications, mammographic breast density, and risk of breast cancer: a cohort study. Breast Cancer Res. 2022; 24: 96.
    OpenUrl
  14. 14.↵
    2. O’Grady S,
    3. Morgan MP.
    Microcalcifications in breast cancer: From pathophysiology to diagnosis and prognosis. Biochim Biophys Acta Rev Cancer. 2018; 1869: 310–20.
    OpenUrl
  15. 15.↵
    2. Tabar L,
    3. Chen HH,
    4. Duffy SW,
    5. Yen MF,
    6. Chiang CF,
    7. Dean PB, et al.
    A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14 mm invasive breast cancers: a prospective study. Lancet. 2000; 355: 429–33.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.
    2. Azam S,
    3. Eriksson M,
    4. Sjolander A,
    5. Gabrielson M,
    6. Hellgren R,
    7. Czene K, et al.
    Mammographic microcalcifications and risk of breast cancer. Br J Cancer. 2021; 125: 759–65.
    OpenUrlPubMed
  17. 17.↵
    2. Qi X,
    3. Chen A,
    4. Zhang P,
    5. Zhang W,
    6. Cao X,
    7. Xiao C.
    Mammographic calcification can predict outcome in women with breast cancer treated with breast-conserving surgery. Oncol Lett. 2017; 14: 79–88.
    OpenUrl
  18. 18.↵
    2. Jin X,
    3. Zhou YF,
    4. Ma D,
    5. Zhao S,
    6. Lin CJ,
    7. Xiao Y, et al.
    Molecular classification of hormone receptor-positive HER2-negative breast cancer. Nat Genet. 2023; 55: 1696–708.
    OpenUrl
  19. 19.↵
    2. Lin CJ,
    3. Xiao WX,
    4. Fu T,
    5. Jin X,
    6. Shao ZM,
    7. Di GH.
    Calcifications in triple-negative breast cancer: molecular features and treatment strategies. NPJ Breast Cancer. 2023; 9: 26.
    OpenUrl
  20. 20.↵
    2. Parker JS,
    3. Mullins M,
    4. Cheang MC,
    5. Leung S,
    6. Voduc D,
    7. Vickery T, et al.
    Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27: 1160–7.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    2. Ciriello G,
    3. Gatza ML,
    4. Beck AH,
    5. Wilkerson MD,
    6. Rhie SK,
    7. Pastore A, et al.
    Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015; 163: 506–19.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Timms KM,
    3. Abkevich V,
    4. Hughes E,
    5. Neff C,
    6. Reid J,
    7. Morris B, et al.
    Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res. 2014; 16: 475.
    OpenUrlCrossRefPubMed
  23. 23.
    2. Telli ML,
    3. Timms KM,
    4. Reid J,
    5. Hennessy B,
    6. Mills GB,
    7. Jensen KC, et al.
    Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016; 22: 3764–73.
    OpenUrlAbstract/FREE Full Text
  24. 24.
    2. Abkevich V,
    3. Timms KM,
    4. Hennessy BT,
    5. Potter J,
    6. Carey MS,
    7. Meyer LA, et al.
    Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012; 107: 1776–82.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.
    2. Birkbak NJ,
    3. Wang ZC,
    4. Kim JY,
    5. Eklund AC,
    6. Li Q,
    7. Tian R, et al.
    Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012; 2: 366–75.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    2. Popova T,
    3. Manie E,
    4. Rieunier G,
    5. Caux-Moncoutier V,
    6. Tirapo C,
    7. Dubois T, et al.
    Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012; 72: 5454–62.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    2. Ock CY,
    3. Hwang JE,
    4. Keam B,
    5. Kim SB,
    6. Shim JJ,
    7. Jang HJ, et al.
    Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat Commun. 2017; 8: 1050.
    OpenUrlCrossRefPubMed
  28. 28.↵
    2. Hanzelmann S,
    3. Castelo R,
    4. Guinney J.
    GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14: 7.
    OpenUrlCrossRefPubMed
  29. 29.↵
    2. Du L,
    3. Yau C,
    4. Brown-Swigart L,
    5. Gould R,
    6. Krings G,
    7. Hirst GL, et al.
    Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy. Ann Oncol. 2021; 32: 642–51.
    OpenUrlCrossRef
  30. 30.
    2. Speers CW,
    3. Symmans WF,
    4. Barlow WE,
    5. Trevarton A,
    6. The S,
    7. Du L, et al.
    Evaluation of the sensitivity to endocrine therapy index and 21-gene breast recurrence score in the SWOG S8814 trial. J Clin Oncol. 2023; 41: 1841–8.
    OpenUrl
  31. 31.↵
    2. Sinn BV,
    3. Fu C,
    4. Lau R,
    5. Litton J,
    6. Tsai TH,
    7. Murthy R, et al.
    Set(ER/PR): a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. NPJ Breast Cancer. 2019; 5: 16.
    OpenUrl
  32. 32.↵
    2. Finn RS,
    3. Liu Y,
    4. Zhu Z,
    5. Martin M,
    6. Rugo HS,
    7. Dieras V, et al.
    Biomarker analyses of response to cyclin-dependent kinase 4/6 inhibition and endocrine therapy in women with treatment-naive metastatic breast cancer. Clin Cancer Res. 2020; 26: 110–21.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    2. Xiao Y,
    3. Ma D,
    4. Yang YS,
    5. Yang F,
    6. Ding JH,
    7. Gong Y, et al.
    Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res. 2022; 32: 477–90.
    OpenUrl
  34. 34.↵
    2. Chen D,
    3. Zhang Y,
    4. Wang W,
    5. Chen H,
    6. Ling T,
    7. Yang R, et al.
    Identification and characterization of robust hepatocellular carcinoma prognostic subtypes based on an integrative metabolite-protein interaction network. Adv Sci (Weinh). 2021; 8: e2100311.
  35. 35.↵
    2. Chen YJ,
    3. Roumeliotis TI,
    4. Chang YH,
    5. Chen CT,
    6. Han CL,
    7. Lin MH, et al.
    Proteogenomics of non-smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression. Cell. 2020; 182: 226–44.e17.
    OpenUrlCrossRef
  36. 36.↵
    2. D’Orsi CJ,
    3. Sickles EA,
    4. Mendelson EB,
    5. Morris EA.
    American College of Radiology; D’Orsi CJ, Sickles EA, Mendelson EB, Morris EA. ACR BI-RADS atlas: breast imaging reporting and data system; mammography, ultrasound, magnetic resonance imaging, follow-up and outcome monitoring, data dictionary. American College of Radiology; 2013.
  37. 37.↵
    2. Spak DA,
    3. Plaxco JS,
    4. Santiago L,
    5. Dryden MJ,
    6. Dogan BE.
    BI-RADS® fifth edition: a summary of changes. Diagn Interv Imaging. 2017; 98: 179–90.
    OpenUrlPubMed
  38. 38.↵
    2. Edelmann J,
    3. Holzmann K,
    4. Tausch E,
    5. Saunderson EA,
    6. Jebaraj BMC,
    7. Steinbrecher D, et al.
    Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. Haematologica. 2020; 105: 1379–90.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    2. Thu KL,
    3. Soria-Bretones I,
    4. Mak TW,
    5. Cescon DW.
    Targeting the cell cycle in breast cancer: towards the next phase. Cell Cycle. 2018; 17: 1871–85.
    OpenUrlCrossRefPubMed
  40. 40.↵
    2. Bai J,
    3. Li Y,
    4. Zhang G.
    Cell cycle regulation and anticancer drug discovery. Cancer Biol Med. 2017; 14: 348–62.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    2. Wolf DM,
    3. Yau C,
    4. Wulfkuhle J,
    5. Brown-Swigart L,
    6. Gallagher IR,
    7. Lee PRE, et al.
    Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022; 40: 609–23.e6.
    OpenUrlCrossRef
  42. 42.↵
    2. Xiao Y,
    3. Ma D,
    4. Zhao S,
    5. Suo C,
    6. Shi J,
    7. Xue MZ, et al.
    Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer. Clin Cancer Res. 2019; 25: 5002–14.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    2. van’ t Veer LJ,
    3. Dai H,
    4. van de Vijver MJ,
    5. He YD,
    6. Hart AA,
    7. Mao M, et al.
    Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415: 530–6.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    2. Yang F,
    3. Foekens JA,
    4. Yu J,
    5. Sieuwerts AM,
    6. Timmermans M,
    7. Klijn JG, et al.
    Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways. Oncogene. 2006; 25: 1413–9.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    2. Symmans WF,
    3. Hatzis C,
    4. Sotiriou C,
    5. Andre F,
    6. Peintinger F,
    7. Regitnig P, et al.
    Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol. 2010; 28: 4111–9.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    2. Hanahan D.
    Hallmarks of cancer: new dimensions. Cancer Discov. 2022; 12: 31–46.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    2. Hakimi AA,
    3. Reznik E,
    4. Lee CH,
    5. Creighton CJ,
    6. Brannon AR,
    7. Luna A, et al.
    An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell. 2016; 29: 104–16.
    OpenUrlCrossRefPubMed
  48. 48.↵
    2. Kulkoyluoglu-Cotul E,
    3. Arca A,
    4. Madak-Erdogan Z.
    Crosstalk between estrogen signaling and breast cancer metabolism. Trends Endocrinol Metab. 2019; 30: 25–38.
    OpenUrlCrossRefPubMed
  49. 49.↵
    2. Zheng K,
    3. Tan JX,
    4. Li F,
    5. Wei YX,
    6. Yin XD,
    7. Su XL, et al.
    Relationship between mammographic calcifications and the clinicopathologic characteristics of breast cancer in western china: a retrospective multi-center study of 7317 female patients. Breast Cancer Res Treat. 2017; 166: 569–82.
    OpenUrl
  50. 50.↵
    2. Kwon BR,
    3. Shin SU,
    4. Kim SY,
    5. Choi Y,
    6. Cho N,
    7. Kim SM, et al.
    Microcalcifications and peritumoral edema predict survival outcome in luminal breast cancer treated with neoadjuvant chemotherapy. Radiology. 2022; 304: 310–9.
    OpenUrl
  51. 51.↵
    2. Cox RF,
    3. Hernandez-Santana A,
    4. Ramdass S,
    5. McMahon G,
    6. Harmey JH,
    7. Morgan MP.
    Microcalcifications in breast cancer: novel insights into the molecular mechanism and functional consequence of mammary mineralisation. Br J Cancer. 2012; 106: 525–37.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Subjects

Keywords